drugset
drugset / Trial / NCT05118750

ALTO-300 in Depression

NCT05118750 ↗

Phase 2 Completed 91 enrolled Alto Neuroscience
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.

Timeline

Start
2021-12-13
Primary completion
2023-05-05
Completion
2023-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ALTO-300 Unknown — Oral

Indications

major depressive disorder